Brought to you by 
Glaxo, Icos develop anti-inflammatory, CV drugs; ended
09 Oct 2003
Executive Summary
Glaxo will collaborate with Icos on the development of anti-inflammatory and cardiovascular therapeutics based on Icos' research on phosphodiesterase (PDE) modulators.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo, Icos develop anti-inflammatory, CV drugs; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice